Browsing Biomedical Sciences by Author "n 89200647"

Now showing items 1-20 of 36

    • Analytic comparison between three high-throughput commercial SARS-CoV-2 antibody assays reveals minor discrepancies in a high-incidence population 

      Nasrallah, Gheyath K; Dargham, Soha R; Shurrab, Farah; Al-Sadeq, Duaa W; Al-Jighefee, Hadeel; ... more authors ( Nature Research , 2021 , Article)
      Performance of three automated commercial serological IgG-based assays was investigated for assessing SARS-CoV-2 "ever" (past or current) infection in a population-based sample in a high exposure setting. PCR and serological ...

    • Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar. 

      Abu-Raddad, Laith J; Chemaitelly, Hiam; Ayoub, Houssein H; Yassine, Hadi M; Benslimane, Fatiha M; ... more authors ( American Medical Association , 2021 , Article)
      The effect of prior SARS-CoV-2 infection on vaccine protection remains poorly understood. To assess protection from SARS-CoV-2 breakthrough infection after mRNA vaccination among persons with vs without prior SARS-CoV-2 ...

    • Associations of Vaccination and of Prior Infection with Positive PCR Test Results for SARS-CoV-2 in Airline Passengers Arriving in Qatar 

      Bertollini, Roberto; Chemaitelly, Hiam; Yassine, Hadi M.; Al-Thani, Mohamed H.; Al-Khal, Abdullatif; ... more authors ( American Medical Association , 2021 , Other)
      The SARS-CoV-2 pandemic has severely affected international travel. With efficacious COVID-19 vaccines available, Qatar implemented a pilot program between February 18 and April 26, 2021, to ease travel restrictions by ...

    • Bivalent mRNA-1273.214 vaccine effectiveness against SARS-CoV-2 omicron XBB* infections 

      Chemaitelly, Hiam; Ayoub, Houssein H.; AlMukdad, Sawsan; Faust, Jeremy S.; Tang, Patrick; ... more authors (2023 , Article)
      In October of 2022, Qatar introduced COVID-19 bivalent vaccination for persons ≥ 12 years using the 50-μg mRNA-1273.214 vaccine combining SARS-CoV-2 ancestral and omicron BA.1 strains.1 We estimated this vaccine’s effectiveness ...

    • BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. 

      Tang, Patrick; Hasan, Mohammad R; Chemaitelly, Hiam; Yassine, Hadi M; Benslimane, Fatiha M; ... more authors ( Nature Researc , 2021 , Article)
      With the global expansion of the highly transmissible SARS-CoV-2 Delta (B.1.617.2) variant, we conducted a matched test-negative case-control study to assess the real-world effectiveness of COVID-19 messenger RNA vaccines ...

    • BNT162b2 antigen dose and SARS-CoV-2 omicron infection in adolescents 

      Chemaitelly, Hiam; Ayoub, Houssein H.; Coyle, Peter; Tang, Patrick; Yassine, Hadi M.; ... more authors ( Elsevier , 2023 , Other)
      COVID-19 vaccine antigen dose might affect protection against SARS-CoV-2 infection,1, 2 but direct evidence to quantify this effect is absent. We conducted a matched, retrospective, cohort study using a regression ...

    • Characterizing the effective reproduction number during the COVID-19 pandemic: Insights from Qatar’s experience 

      Bsat, Raghid; Chemaitelly, Hiam; Coyle, Peter; Tang, Patrick; Hasan, Mohammad R; ... more authors ( International Society of Global Health , 2022 , Article)
      Background: The effective reproduction number, Rt, is a tool to track and understand epidemic dynamics. This investigation of Rt estimations was conducted to guide the national COVID-19 response in Qatar, from the onset ...

    • Coronavirus Disease 2019 Disease Severity in Children Infected With the Omicron Variant 

      Butt, A.A.; Butt, Adeel A.; Dargham, Soha R.; Loka, Srusvin; Shaik, Riyazuddin M.; ... more authors ( NLM (Medline) , 2022 , Article)
      SHORT SUMMARY: Severe acute respiratory syndrome coronavirus 2 infection from the Omicron variant in children/adolescents is less severe than infection from the Delta variant. Those 6 to <18 years also have less severe ...

    • Duration of immune protection of SARS-CoV-2 natural infection against reinfection. 

      Chemaitelly, Hiam; Nagelkerke, Nico; Ayoub, Houssein H; Coyle, Peter; Tang, Patrick; ... more authors ( Oxford University Press , 2022 , Article)
      The future of the SARS-CoV-2 pandemic hinges on virus evolution and duration of immune protection of natural infection against reinfection. We investigated duration of protection afforded by natural infection, the effect ...

    • Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar. 

      Chemaitelly, Hiam; Ayoub, Houssein H; AlMukdad, Sawsan; Coyle, Peter; Tang, Patrick; ... more authors ( Nature Research , 2022 , Article)
      SARS-CoV-2 Omicron BA.1 and BA.2 subvariants are genetically divergent. We conducted a matched, test-negative, case-control study to estimate duration of protection of the second and third/booster doses of mRNA COVID-19 ...

    • Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar. 

      Abu-Raddad, Laith J; Chemaitelly, Hiam; Ayoub, Houssein H; AlMukdad, Sawsan; Yassine, Hadi M; ... more authors ( Massachusetts Medical Society , 2022 , Article)
      Waning of vaccine protection against coronavirus disease 2019 (Covid-19) and the emergence of the omicron (or B.1.1.529) variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have led to expedited ...

    • Effects of BA.1/BA.2 subvariant, vaccination, and prior infection on infectiousness of SARS-CoV-2 omicron infections. 

      Qassim, Suelen H; Chemaitelly, Hiam; Ayoub, Houssein H; AlMukdad, Sawsan; Tang, Patrick; ... more authors ( Oxford University Press , 2022 , Article)
      Compared to BA.1, BA.2 was associated with lower RT-qPCR cycle threshold (Ct) value-3.53 fewer cycles (95% CI: 3.46-3.60), signifying higher infectiousness. This may reflect higher viral load and/or longer duration of ...

    • Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections. 

      Altarawneh, Heba N; Chemaitelly, Hiam; Ayoub, Houssein H; Tang, Patrick; Hasan, Mohammad R; ... more authors ( Massachusetts Medical Society , 2022 , Article)
      The protection conferred by natural immunity, vaccination, and both against symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with the BA.1 or BA.2 sublineages of the omicron (B.1.1.529) ...

    • Effects of previous infection, vaccination, and hybrid immunity against symptomatic Alpha, Beta, and Delta SARS-CoV-2 infections: an observational study 

      Heba N., Altarawneh; Chemaitelly, Hiam; Ayoub, Houssein H.; Tang, Patrick; Hasan, Mohammad R.; ... more authors ( Elsevier , 2023 , Article)
      BackgroundProtection against SARS-CoV-2 symptomatic infection and severe COVID-19 of previous infection, mRNA two-dose vaccination, mRNA three-dose vaccination, and hybrid immunity of previous infection and vaccination ...

    • Effects of SARS-CoV-2 Alpha, Beta, and Delta variants, age, vaccination, and prior infection on infectiousness of SARS-CoV-2 infections 

      Qassim, Suelen H.; Hasan, Mohammad R.; Tang, Patrick; Chemaitelly, Hiam; Ayoub, Houssein H.; ... more authors ( Frontiers Media , 2022 , Article)
      In 2021, Qatar experienced considerable incidence of SARS-CoV-2 infection that was dominated sequentially by the Alpha, Beta, and Delta variants. Using the cycle threshold (Ct) value of an RT-qPCR-positive test to proxy ...

    • Epidemiological impact of prioritising SARS-CoV-2 vaccination by antibody status: Mathematical modelling analyses 

      Ayoub, H.H.; Ayoub, Houssein H.; Chemaitelly, Hiam; Makhoul, Monia; Al Kanaani, Zaina; ... more authors ( BMJ Publishing Group , 2021 , Article)
      Background Vaccines against SARS-CoV-2 have been developed, but their availability falls far short of global needs. This study aimed to investigate the impact of prioritising available doses on the basis of recipient ...

    • Estimating protection afforded by prior infection in preventing reinfection: Applying the test-negative study design. 

      Ayoub, Houssein H; Tomy, Milan; Chemaitelly, Hiam; Altarawneh, Heba N; Coyle, Peter; ... more authors ( Oxford University Press , 2023 , Article)
      The COVID-19 pandemic has highlighted the need to use infection testing databases to rapidly estimate effectiveness of prior infection in preventing reinfection ($P{E}_S$) by novel SARS-CoV-2 variants. Mathematical modeling ...

    • History of primary-series and booster vaccination and protection against Omicron reinfection 

      Chemaitelly, Hiam; Ayoub, Houssein H.; Tang, Patrick; Coyle, Peter V.; Yassine, Hadi M.; ... more authors ( American Association for the Advancement of Science , 2023 , Article)
      Laboratory evidence suggests a possibility of immune imprinting for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We investigated the differences in the incidence of SARS-CoV-2 reinfection in a ...

    • Immune Imprinting and Protection against Repeat Reinfection with SARS-CoV-2 

      Chemaitelly, Hiam; Ayoub, Houssein H.; Tang, Patrick; Hasan, Mohammad R.; Coyle, Peter; ... more authors ( Massachusetts Medical Society , 2022 , Other)
      More than 2 years into the coronavirus disease 2019 (Covid-19) pandemic, the global population carries heterogeneous immune histories derived from various exposures to infection, viral variants, and vaccination.1 Evidence ...

    • Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study 

      Hiam, Chemaitelly; Ayoub, Houssein H; Tang, Patrick; Coyle, Peter; Yassine, Hadi M; ... more authors ( Elsevier , 2023 , Article)
      BackgroundLong-term effectiveness of COVID-19 mRNA boosters in populations with different previous infection histories and clinical vulnerability profiles is inadequately understood. We aimed to investigate the effectiveness ...